Drug
Acalabrutinib
Acalabrutinib: highest development phase Phase 2, developed by TG Therapeutics. 1 trial record tracked on RxWires.
- Highest phase
- Phase 2
- Developer
- TG Therapeutics
Trials
| Drug | Phase | Indication |
|---|---|---|
| Acalabrutinib NCT04624633 | Phase 2 | Chronic Lymphocytic Leukemia |
Latest
No recent events.
Follow Acalabrutinib on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.